pancreatic cancer pancreatic ductal adenocarcinoma
Conditions
Interventions
The intervention consists of 2 additional blood draws during a standard visit
to the outpatient clinic. During each visit 5 additional tubes of blood (43 ml)
will be collected.
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: * Age * 18 years * Diagnosed with (borderline) resectable, locally advanced or metastasized pancreatic cancer * Treatment with FOLFIRINOX chemotherapy, including neoadjuvant and adjuvant therapy * Written informed consent
Exclusion criteria
Exclusion criteria: * Combined treatment with other chemotherapeutics then FOLFIRINOX * Previous treatment with FOLFIRINOX chemotherapy * Pregnancy * Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| * Response rate * Number of adverse events * Resection rate * Progression free survival * Overall survival. | — |
Primary
| Measure | Time frame |
|---|---|
| Differences in expression between responders and non-responders and between patients who experience severe toxicity and those who do not, based on: * SNPs * ctDNA mutations * miRNA patterns * Microbiome patterns * Immune profiles | — |
Countries
Netherlands
Outcome results
None listed